NASDAQ:ICCC

Immucell Stock News

Healthcare > Biotechnology

Buy ICCC

*Your capital is at risk

$11.21

+0.150 (+1.36%)

At Close: Jul 31, 2026

ImmuCell Reports Q1 EPS $0.11 vs. Prior Year Quarter $0.15, Rev. $2.98M vs. Prior Year Quarter $3.101M

12:00am, Wednesday, 11'th May 2016

ImmuCell Reports Q4 EPS $0.09 vs. Prior Year Quarter $0.04, Rev. $2.7M

12:00am, Wednesday, 10'th Feb 2016

ImmuCell Prices 1.123M Shares At $5.25/Share

12:00am, Friday, 29'th Jan 2016

ImmuCell Reports Sees FY15 Rev. $10.2M, EPS $0.34-$0.41

12:00am, Thursday, 28'th Jan 2016

Immucell Reports Purchase of Certain Assets from DAY1 Technology of Minnesota, No Terms Disclosed

12:00am, Wednesday, 06'th Jan 2016

ImmuCell Reports Entering of New Contract with Norbrook

12:00am, Tuesday, 22'nd Dec 2015

Morning Market Gainers

12:00am, Friday, 13'th Nov 2015

Immucell Reports Q3 EPS $0.11, Sales $2.47M, no estimates

12:00am, Thursday, 12'th Nov 2015

ImmuCell Reports Q2 EPS $0.18, Sales $1.96M

12:00am, Thursday, 13'th Aug 2015

UPDATE: ImmuCell Raises Q2 Sales Outlook

12:00am, Wednesday, 08'th Jul 2015

Morning Market Gainers

12:00am, Wednesday, 13'th May 2015

Immucell Stock News

ImmuCell Reports Q1 EPS $0.11 vs. Prior Year Quarter $0.15, Rev. $2.98M vs. Prior Year Quarter $3.101M

ImmuCell Reports Q4 EPS $0.09 vs. Prior Year Quarter $0.04, Rev. $2.7M

ImmuCell Prices 1.123M Shares At $5.25/Share

ImmuCell Reports Sees FY15 Rev. $10.2M, EPS $0.34-$0.41

Immucell Reports Purchase of Certain Assets from DAY1 Technology of Minnesota, No Terms Disclosed

ImmuCell Reports Entering of New Contract with Norbrook

Morning Market Gainers

Immucell Reports Q3 EPS $0.11, Sales $2.47M, no estimates

ImmuCell Reports Q2 EPS $0.18, Sales $1.96M

UPDATE: ImmuCell Raises Q2 Sales Outlook

Morning Market Gainers

ImmuCell's (ICCC) CEO Michael Brigham on Q1 2015 Results - Earnings Call Transcript

ImmuCell Reports Positive Results From Rotavirus Pivotal Effectiveness Study

Top Fintech Company